Trial design {8}
DISEASE, ACUTE LEUKEMIA
The FOVOCIP study is a randomized, open-label, phase III clinical trial with a non-inferiority design, in which patients are randomized in a 1:1 ratio into two parallel, controlled prophylaxis groups: fosfomycin or ciprofloxacin. The groups are stratified by site and by underlying disease (acute leukemia or stem cell transplantation).FOVOCIP is a pragmatic study and very well adapted to the usual clinical practice of the sites of the public health system in Spain.